SCHEMBL985740

SCHEMBL985740

Nc1ncccc1C(=O)Nc1cccc(Cl)c1Cl

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.64
PRKCI P41743 2/20 0.57
KDR P35968 1/20 0.56
PABPC1 P11940 1/20 0.55
EIF4H Q15056 1/20 0.55
LMNA P02545 2/20 0.51
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 1/20 0.51
VCP P55072 1/20 0.49
EPHB3 P54753 1/20 0.49
JAK2 O60674 1/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
HPGD P15428 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C19 P33261 1/20 0.49
RAB9A P51151 2/20 0.48
MAPT P10636 3/20 0.48
NPC1 O15118 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL985515 0.86 PRKCI (0.55) GAAPRKCIKDRPABPC1EIF4H
SCHEMBL985509 0.82 ATR (0.56) GAAPRKCILMNAKDM4EALDH1A1
SCHEMBL982425 0.81 GAA (0.46) GAAPRKCIKDRPABPC1EIF4H
SCHEMBL982424 0.81 GAA (0.46) GAAPRKCIKDRPABPC1EIF4H
SCHEMBL12982110 0.78 CHRNA7 (0.63) PRKCI
SCHEMBL982570 0.78 GAA (0.61) GAAKDRPABPC1EIF4HLMNA
SCHEMBL29217384 0.78 ALDH1A1 (0.67) GAALMNAALDH1A1MEN1KMT2A
SCHEMBL985872 0.78 PRKCI (0.57) PRKCIKDRKDM4EALDH1A1VCP
SCHEMBL12857647 0.75 PRKCI (0.75) PRKCIKDRLMNAKDM4EALDH1A1
SCHEMBL9621501 0.75 LMNA (0.67) GAALMNAKDM4EALDH1A1EPHB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101479255-B C-MET protein kinase inhibitors for the treatment of proliferative disorders VERTEX PHARMA 2013-05-01 CN disclosed
US-8232406-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-31 US disclosed
US-20110059936-A1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-10 US disclosed
US-7872031-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-18 US disclosed
EP-2004625-B1 C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS VERTEX PHARMA (US) 2009-12-30 EP disclosed
EP-2004625-A2 C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Vertex Pharmaceuticals Incorporated (US) 2008-12-24 EP disclosed
US-20070254868-A1 C-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-11-01 US disclosed
WO-2007111904-A2 C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059936-A1 C-MET PROTEIN KINASE INHIBITORS MET, PRKCH, ABL1 GAA 1570/4885PRKCI 4/4885KDR 232/4885
US-20070254868-A1 C-MET protein kinase inhibitors MET, PRKCH, ABL1 GAA 1570/4885PRKCI 4/4885KDR 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.